3.Leong, J, Salek, S, Walker, S (2014) Strategy for communicating benefit-risk decisions: a comparison of regulatory agencies' publicly available documents. Front Pharmacol. 5(269), 1–9.
5.Mt-Isa, S, Hallgreen, CE, Wang, N et al. (2014) Balancing benefit and risk of medicines: a systematic review and classification of available methodologies. Pharmacoepidemiol Drug Saf 23(7), 667–678.
6.Mt-Isa, S, Ouwens, B, Robert, V et al. (2016) Structured benefit-risk assessment: a review of key publications and initiatives on frameworks and methodologies. Pharma Stat. 15, 4.
7.Pignatti, F, Ashby, D, Brass, EP et al. (2015) Structured frameworks to increase the transparency of the assessment of benefits and risks of medicines: current status and possible future direction. Clin Pharmacol Ther. 98(5), 522–533.
10.Walker, S, McAuslane, N, Liberti, L, Leong, J, Salek, S (2015) A universal framework for the benefit-risk assessment of medicines: is this the way forward? Ther Innov Regul Sci. 49(1), 17–25.
12.MacKean, G, Noseworthy, T, Elshaug, AG et al. (2013) Health technology reassessment: the art of the possible. Int J Technol Assess Health Care. 29, 418–423.
13.Maloney, MA, Schwartz, L, O'Reilly, D, Levine, M (2017) Drug disinvestment frameworks: components, challenges and solutions. Int J Technol Assess Health Care. 33, 261–269.
14.Seo, HJ, Park, JJ, Lee, SH (2016) A systematic review on current status of health technology reassessment: insights for South Korea. Health Res Policy Sys. 14, 1–10.
15.Soril, LJ, MacKean, G, Noseworthy, TW, Leggett, LE, Clement, FM (2017) Achieving optimal technology use: a proposed model for health technology reassessment. SAGE Open Med. 5, 1–7.
18.Sullivan-Bolyai, S (2005) Developing and refining interventions in persons with health disparities: the use of qualitative description. Nurs Outlook. 53, 127–133.
19.Neergaard, MA, Olesen, F, Andersen, RS, Sondergaard, J (2009) Qualitative description—the poor cousin of health research? BMC Med Res Methodol. 9, 52–57.
20.Sandelowski, M (2000) Whatever happened to qualitative description? Res Nurs Health. 23, 334–340.
21.Creswell, JW (2013) Qualitative inquiry and research design: choosing among five traditions. 3rd ed. Thousand Oaks: Sage Publications.
22.Miles, MB, Huberman, AM (1994) Qualitative data analysis—an expanded sourcebook. 2nd ed. Thousand Oaks: Sage Publications.
23.Smith, JA (2007) Qualitative psychology: a practical guide to research methods. 2nd ed. London: Sage Publications.
24.Glaser, BG (1965) The constant comparative method of qualitative analysis. Soc Probl. 12(4), 436–445.
25.Fram, S (2013) The constant comparative analysis method outside of grounded theory. Qual Rep. 18(1), 1–25.
26.Emden, C, Sandelowski, M (1998) The good, the bad, and the relative, part one: conceptions of goodness in qualitative research. Int J Nurs Pract. 4, 206–212.
27.Whittemore, R, Chase, S, Mandle, C (2001) Validity in qualitative research. Qual Health Res. 11, 522–537.
28.Milne, J, Oberle, K (2005) Enhancing rigor in qualitative description: a case study. J Wound Ostomy Continence Nurs. 32, 413–420.
33.Henshall, C, Schuller, T, Mardhani-Bayne, L (2012) Using health technology assessment to support optimal use of technologies in current practice: the challenge of “disinvestment”. Int J Technol Assess Health Care. 28, 203–210.
34.Esmail, R, Hanson, H, Holroyd-Leduc, J, Niven, DJ, Clement, F (2018) Knowledge translation and health technology reassessment: identifying synergy. BMC Health Serv Res. 18(1), 674–682.
35.Giorgi, A (1992) Description versus interpretation: competing alternative strategies for qualitative research. J Phenomenol Psychol. 23, 119–135. 10.1163/156916292X00090.